Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 12/20 | 0.45 |
| ▸ | LOX | P28300 | 4/20 | 0.45 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13541414 | 0.84 | RECQL (0.61) | RECQLLOXL2LOXLOXL3PLAU | |
| SCHEMBL4107151 | 0.84 | LOXL2 (0.61) | LOXL2LOXLOXL3NOS3NOS1 | |
| SCHEMBL9817617 | 0.83 | LOXL2 (0.55) | RECQLLOXL2LOXLOXL3 | |
| Hydrochloric Acid SCHEMBL5013442 | 0.82 | LOXL2 (0.59) | LOXL2LOXLOXL3NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL17372124 | 0.81 | LOXL2 (0.53) | RECQLLOXL2LOXLOXL3 | |
| SCHEMBL2935815 | 0.78 | RECQL (0.55) | RECQLPLAUPRKCINOS3NOS1 | |
| SCHEMBL16583871 | 0.78 | LOXL2 (0.52) | RECQLLOXL2LOXLOXL3 | |
| SCHEMBL21393240 | 0.78 | RECQL (0.55) | RECQLLOXL2LOXLOXL3PLAU | |
| SCHEMBL2642379 | 0.78 | RECQL (0.55) | RECQLLOXL2LOXLOXL3PLAU | |
| SCHEMBL15200880 | 0.78 | NOS3 (0.61) | LOXL2LOXLOXL3NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939320-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20210171508-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-06-10 | — | — | US | disclosed |
| CN-112166113-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-01 | — | — | CN | disclosed |
| EP-3704115-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-8765789-B2 | 2-pyridinecarboxamide derivatives | MSD K.K. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20130085156-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD K.K. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8344003-B2 | 2-pyridinecarboxamide derivatives | MSD K. K. (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD K.K. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-7629362-B2 | 2-pyridine carboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1598349-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-23 | — | — | EP | disclosed |
| US-3952101-A | BETA ADRENERGIC STIMULANT | SMITHKLINE CORPORATION (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085156-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | GCKR, GCK, HK2 | RECQL 4077/4885LOXL2 2232/4885LOX 1831/4885 |
| US-11939320-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | RECQL 2318/4885LOXL2 2584/4885LOX 2259/4885 |
| US-20210171508-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | RECQL 2318/4885LOXL2 2584/4885LOX 2259/4885 |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | GCKR, GCK, HK2 | RECQL 4000/4885LOXL2 2252/4885LOX 1812/4885 |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | GCKR, GCK, HK2 | RECQL 4077/4885LOXL2 2232/4885LOX 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.